相关实验视频

Updated: Jul 1, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

用生物药物治疗IgA脏病的进展

Yongze Zhuang¹, Hailing Lu¹, Junxia Li¹

¹Department of Nephrology, 900 Hospital of the Joint Logistics Team, PLA, Fuzhou General Clinical Medical College Fujian Medical University Fuzhou Fujian China.

Chronic diseases and translational medicine

|March 7, 2024

概括

免疫球蛋白A脏病 (IgAN) 是一种常见的脏疾病. 新兴的生物疗法在减少蛋白尿和改善功能方面表现有希望,尽管需要进一步的研究.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

免疫球蛋白A脏病 (IgAN) 是主要的原发性质细胞疾病.
这是一个很棒的节目,这是一个很棒的节目.
四次击中四次击中
理论概述了其致病性,涉及粘膜免疫,T和B细胞激活和IgA生产.
目前的治疗方法,如氨酸- ангиотензин- 阿尔多素系统抑制剂,对于IgAN缺乏特定的疗效.

研究的目的:

审查目前对IGAN病变的理解.
探索生物药物的潜力,作为IGAN的新疗法策略.
分类和讨论正在研究Igan治疗的不同类别的生物制剂.

主要方法:

关于IgAN病原和当前治疗方法的文献综述.
对针对IgAN的关键途径的生物制剂最近的研究分析.
根据其作用机制对生物制剂进行分类.

主要成果:

生物药物显示出降低蛋白尿的潜力,稳定膜过率,并逆转IgAN的病理变化.
已经确定了四种主要类型的生物药物:抗CD20,抗BLyS/APRIL,双抗BLyS/APRIL和补充抑制剂.
具体的药物包括纳索普利马布,埃库利祖马布,特利塔西塞普和阿塔西塞普.

结论:

生物药物代表了IGAN治疗的有前途的新途径,提供了超越当前疗法的潜在好处.
为了确定这些药物的最佳剂量,治疗持续时间,长期疗效和安全性,需要进行进一步的研究.
针对性生物疗法的开发可能会显著改变Igan患者的管理环境.

关键词:

4月份的时间.布莱斯 (BlyS) 是一个叫做BlyS的词.在IgA脏病发作中,IgA脏病发作对抗CD20单克隆抗体的抗体.生物制剂生物制剂是生物制剂.补充补充补充补充补充补充补充.

更多相关视频

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...